Amneal Pharmaceuticals (AMRX) Aandelenoverzicht
Amneal Pharmaceuticals, Inc., een wereldwijd biofarmaceutisch bedrijf, ontwikkelt, produceert, verkoopt en distribueert generieke geneesmiddelen, injecteerbare geneesmiddelen, biosimilars en farmaceutische specialiteiten onder merknaam in de Verenigde Staten, India, Ierland en internationaal. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 3/6 |
| Toekomstige groei | 4/6 |
| Prestaties in het verleden | 2/6 |
| Financiële gezondheid | 1/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
AMRX Community Fair Values
Create NarrativeSee what 23 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Amneal Pharmaceuticals, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$12.83 |
| 52 Week Hoogtepunt | US$15.42 |
| 52 Week Laag | US$7.02 |
| Bèta | 1.32 |
| 1 maand verandering | 0.94% |
| 3 maanden verandering | -6.21% |
| 1 Jaar Verandering | 60.98% |
| 3 jaar verandering | 568.23% |
| 5 jaar verandering | 146.73% |
| Verandering sinds IPO | -14.52% |
Recent nieuws en updates
Amneal: A Robust Drug Portfolio Worth Watching, Driving Further Upside Potential
Apr 21
AMRX: 2026 EBITDA Plan And Inhalation Entry Will Drive Bullish Setup
Amneal Pharmaceuticals' analyst price target has shifted from $16.80 to about $17.17, with analysts pointing to recent target increases to $17 following solid Q4 results, 2026 EBITDA guidance strength, and a still intact long term growth thesis as key support for the updated view. Analyst Commentary Recent Street research around Amneal Pharmaceuticals has been concentrated on Q4 results, the new 2026 outlook, and how these feed into revised targets near $17.Recent updates
Amneal: A Robust Drug Portfolio Worth Watching, Driving Further Upside Potential
Apr 21AMRX: 2026 EBITDA Plan And Inhalation Entry Will Drive Bullish Setup
Amneal Pharmaceuticals' analyst price target has shifted from $16.80 to about $17.17, with analysts pointing to recent target increases to $17 following solid Q4 results, 2026 EBITDA guidance strength, and a still intact long term growth thesis as key support for the updated view. Analyst Commentary Recent Street research around Amneal Pharmaceuticals has been concentrated on Q4 results, the new 2026 outlook, and how these feed into revised targets near $17.AMRX: 2026 EBITDA Plan And Affordable Medicines Theme Will Drive Bullish Setup
Analysts have raised their price targets on Amneal Pharmaceuticals from $15 to $17, citing solid Q4 results, 2026 guidance that highlights stronger EBITDA expectations, and continued interest in the affordable medicines theme as key supports for the updated view. Analyst Commentary Analysts raising targets to $17 are largely focused on how Amneal executes against its 2026 plan and how that ties into the affordable medicines theme and EBITDA outlook.AMRX: 2026 EBITDA Guidance Will Shape Bullish Setup Despite Recent Pullback
Narrative Update on Amneal Pharmaceuticals The analyst price target for Amneal Pharmaceuticals has been revised higher from $16.40 to $16.80. Analysts point to stronger FY26 EBITDA guidance and recent target increases to $17 at multiple firms as support for the updated view.AMRX: 2026 EBITDA Outlook And Index Adds Will Shape Bullish Setup
Analysts have lifted their price target on Amneal Pharmaceuticals from $15.20 to $16.40, citing recent target hikes to $17 following solid Q4 results and 2026 guidance. The guidance highlights stronger EBITDA expectations despite more tempered revenue and margin assumptions, along with a higher future P/E of about 50x.AMRX: Affordable Medicines Theme And Index Adds Will Shape Measured 2026 Setup
Analysts have nudged their price targets on Amneal Pharmaceuticals higher, with the updated fair value estimate moving from $14.40 to $15.20. This change is supported by recent Street research highlighting continued interest in affordable medicines and the company's role in that theme.AMRX: Affordable Medicines Theme And Index Adds Will Shape Balanced 2026 Outlook
Analysts recently lifted their price target on Amneal Pharmaceuticals to $15 from $14, citing the company’s exposure to the affordable medicines theme as a key factor supporting their updated view. Analyst Commentary Recent commentary around Amneal Pharmaceuticals centers on its role in the affordable medicines theme and how that ties into expectations for execution and valuation heading into 2026.AMRX: Affordable Medicines Theme And Q3 Execution Will Guide Fairly Balanced Outlook
Narrative Update Analysts have lifted their implied price target on Amneal Pharmaceuticals to about $14.40 from $14, reflecting higher Street targets of up to $15 and supportive views on both the affordable medicines theme and the company’s recent Q3 results versus expectations. Analyst Commentary Recent research updates focus on Amneal Pharmaceuticals' role in affordable medicines and the implications of its latest quarterly results for valuation and execution.AMRX: Complex Generics Pipeline And Recent EPS Beat Will Shape Outlook
Analysts have nudged their fair value estimate for Amneal Pharmaceuticals higher to US$14.00 from US$13.80, reflecting updated price targets and recent quarterly results that came in ahead of prior Street EPS and revenue estimates. Analyst Commentary Bullish Takeaways Bullish analysts highlight that Q3 adjusted diluted EPS of US$0.17 came in ahead of prior Street expectations of US$0.14, which they see as a sign of solid execution against current earnings targets.AMRX: Complex Generics Approvals Will Support Future Earnings Upside
Analysts have modestly raised their price target on Amneal Pharmaceuticals to approximately $13.80 from about $13.50, reflecting better than expected earnings and revenue performance in the latest quarter. Analyst Commentary Bullish Takeaways Bullish analysts highlight the earnings beat, with adjusted diluted EPS exceeding Street expectations, as evidence that management is executing effectively on cost control and product mix.Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Nov 30
AMRX: Continued Execution and Pipeline Milestones Will Support Balanced Outlook
Analysts have raised their price target for Amneal Pharmaceuticals from $11 to $13, citing the company's stronger than expected third-quarter results and improved earnings outlook. Analyst Commentary Following the recent quarterly results, analysts have weighed in on Amneal Pharmaceuticals with a focus on both the company's strengths and areas for caution as they consider the revised price target.AMRX: Sustained Outperformance Will Drive Future Earnings Confidence
Analysts have increased their price target for Amneal Pharmaceuticals from $11 to $13. They cite the company’s better-than-expected third-quarter earnings and revenue performance as the reason for this adjustment.Amneal Pharmaceuticals' (NASDAQ:AMRX) Earnings May Just Be The Starting Point
Nov 14AMRX: Recent FDA Approvals And Pipeline Launches Will Drive Upside Momentum
Amneal Pharmaceuticals’ analyst price target has risen from $12.67 to $13.50, as analysts cite stronger revenue growth and an improved earnings outlook following the company’s recent results. Analyst Commentary Recent analyst updates indicate a mix of optimism and caution following Amneal Pharmaceuticals’ latest quarterly performance and forward guidance.Global Health Trends And Pipeline Launches Will Fuel Future Potential
Amneal Pharmaceuticals' consensus price target has been raised as analysts now assign a higher future P/E multiple, increasing their fair value estimate from $12.00 to $12.67. What's in the News Amneal received FDA approval for its sodium oxybate oral solution 500 mg/mL (generic for Xyrem) for narcolepsy, expanding beyond prior limited authorized generic distribution.Results: Amneal Pharmaceuticals, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Aug 08Why Investors Shouldn't Be Surprised By Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Low P/S
Jul 24
CREXONT And Metsera Partnerships Will Capitalize On Growing GLP-1 Market
The strategic collaboration in GLP-1 therapies and biosimilars expands market reach, poised to drive significant future revenue growth.Amneal Pharmaceuticals: Shares Still Feel Significantly Undervalued
Mar 19There's No Escaping Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Muted Revenues
Feb 17Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price
Nov 10Rendement voor aandeelhouders
| AMRX | US Pharmaceuticals | US Markt | |
|---|---|---|---|
| 7D | 2.5% | 3.3% | 0.8% |
| 1Y | 61.0% | 27.3% | 27.7% |
Rendement versus industrie: AMRX overtrof de US Pharmaceuticals industrie, die het afgelopen jaar een rendement 27.3 % opleverde.
Rendement versus markt: AMRX overtrof de US markt, die het afgelopen jaar een rendement opleverde van 27.7 %.
Prijsvolatiliteit
| AMRX volatility | |
|---|---|
| AMRX Average Weekly Movement | 4.9% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.3% |
Stabiele aandelenkoers: AMRX heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 5% ) van AMRX is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2002 | 8,700 | Chirag Patel | www.amneal.com |
Amneal Pharmaceuticals, Inc., een wereldwijd biofarmaceutisch bedrijf, ontwikkelt, produceert, verkoopt en distribueert generieke geneesmiddelen, injecteerbare geneesmiddelen, biosimilars en farmaceutische specialiteiten onder merknaam in de Verenigde Staten, India, Ierland en internationaal. Het bedrijf is actief in drie segmenten: Betaalbare Geneesmiddelen, Specialiteiten en AvKARE. Het segment Betaalbare Geneesmiddelen biedt doseringsvormen en afgiftesystemen aan, waaronder orale vaste stoffen, poeders, vloeistoffen, steriele injectables, neussprays, inhalatie- en ademhalingsproducten, biosimilaire producten, oogheelkundige producten, films, transdermale pleisters en topicale producten met directe en verlengde afgifte.
Amneal Pharmaceuticals, Inc. Samenvatting
| AMRX fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$4.11b |
| Inkomsten(TTM) | US$72.06m |
| Inkomsten(TTM) | US$3.02b |
Is AMRX overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| AMRX resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$3.02b |
| Kosten van inkomsten | US$1.89b |
| Brutowinst | US$1.13b |
| Overige uitgaven | US$1.06b |
| Inkomsten | US$72.06m |
Laatst gerapporteerde inkomsten
Dec 31, 2025
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 0.23 |
| Brutomarge | 37.38% |
| Nettowinstmarge | 2.39% |
| Schuld/Eigen Vermogen Verhouding | 43,130.6% |
Hoe presteerde AMRX op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/01 21:13 |
| Aandelenkoers aan het einde van de dag | 2026/05/01 00:00 |
| Inkomsten | 2025/12/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Amneal Pharmaceuticals, Inc. wordt gevolgd door 20 analisten. 5 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Glen Santangelo | Barclays |
| Gary Nachman | BMO Capital Markets Equity Research |
| David Buck | B. Riley Securities, Inc. |